Osprey to market efficiency of DyeVert

Osprey Medical has received FDA clearance for expanded marketing claims of dye savings, image quality and reflux reduction for the DyeVert System.

The new expanded claims enable physicians to comply with cardiology and radiology society guidelines that urge physicians to use dye sparing approaches in patients at risk of contrast induced acute kidney injury.

Clinical use of the DyeVert System in over 100 patients from three different hospitals have shown an average of more than 45% dye savings without compromised image quality.